Pasithea Therapeutics To Present Phase I Dose-Escalation Study Of Safety, Pharmacokinetics Of PAS-004, Macrocyclic MEK Inhibitor, For Treatment Of MAPK Pathway Driven Advanced Solid Tumors At ESMO Congress 2026

뉴스 본문을 불러오고 있어요.

Pasithea Therapeutics To Present Phase I Dose-Escalation Study Of Safety, Pharmacokinetics Of PAS-004, Macrocyclic MEK Inhibitor, For Treatment Of MAPK Pathway Driven Advanced Solid Tumors At ESMO Congress 2026 | 웨이프 WAPE

Pasithea Therapeutics To Present Phase I Dose-Escalation Study Of Safety, Pharmacokinetics Of PAS-004, Macrocyclic MEK Inhibitor, For Treatment Of MAPK Pathway Driven Advanced Solid Tumors At ESMO Congress 2026

기사 요약

관련 종목

댓글 —